Business
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop
About this update from Cellectis S.a.
[{"type":"image","alt":"Cellectis Inc.","displaySize":"","headline":null,"caption":"Cellectis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U3etrkPEbdAWocW4KkNDeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97","width":300,"height":119}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistence","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"IL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026","length":81,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":295,"olType":false},{"type":"text","content":"NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.","length":457,"tagName":"p"},{"type":"text","content":"Eti-cel product candidate is the first allogeneic dual CAR-T targeting CD20 and CD22 simultaneously, being developed in Phase 1 of the NATHALI-01 clinical trial, for patients with relapsed/refractory non-Hodgkin lymphoma (r/r NHL), following at least two lines of therapy.","length":272,"tagName":"p"},{"type":"text","content":"Cellectis presented preliminary results on eti-cel, which demonstrated an encouraging overall response rate (ORR) of 88% and a complete response (CR) rate of 63% (n=8) at the current dose level.","length":194,"tagName":"p"},{"type":"text","content":"Additional in vivo data presented suggest that exogenous low dose Interleukin-2 (IL-2) support can significantly enhance the expansion and persistence of CAR-T cells to boost CAR...